NCT06563401 Mortality and Cardiovascular Diseases in Adult-onset Type 1 Diabetes
| NCT ID | NCT06563401 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Karolinska Institutet |
| Condition | Type 1 Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 900,000 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2025-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900,000 participants in total. It began in 2024-01-01 with a primary completion date of 2025-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Scarce evidence is available for prognosis in adult-onset type 1 diabetes (T1D). The aim of this study is to investigate the risk of all-cause mortality, cause-specific mortality, and incident CVD in adult-onset T1D, as compared to type 2 diabetes with comparable age at diagnosis and population controls. We will explore potential modifiable factors including lifestyle and clinical characteristics that contribute to T1D prognosis. In addition, we will estimate the life expectancy associated with different age at T1D diagnosis as compared to population controls. This study will be based on people with diabetes recorded in Swedish National Diabetes Registers, with linkages to other nationwide registers to retrieve data on lifestyle factors, biomarkers, treatment and outcome information.
Eligibility Criteria
Inclusion Criteria: * people with adult-onset (≥18 years) T1D diagnosed in 2001-2020 from the National Diabetes Register * all T2D cases diagnosed at age ≥18 years in 2001-2020 recorded in the National Diabetes Register Everyone with T1D was matched by age, sex, and county to 50 population controls from the Total Population Register. Exclusion Criteria: * To avoid diabetes secondary to pancreatic cancer, we excluded people diagnosed with cancer in the digestive system 1 year prior to diabetes diagnosis and with pancreatic cancer as the underlying cause of death.
Contact & Investigator
Sofia Carlsson, phd
PRINCIPAL INVESTIGATOR
sofia carlsson, senior lecturer, Karolinska Institutet
Frequently Asked Questions
Who can join the NCT06563401 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Type 1 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06563401 currently recruiting?
Yes, NCT06563401 is actively recruiting participants. Contact the research team at sofia.carlsson@ki.se for enrollment information.
Where is the NCT06563401 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT06563401 clinical trial?
NCT06563401 is sponsored by Karolinska Institutet. The principal investigator is Sofia Carlsson, phd at sofia carlsson, senior lecturer, Karolinska Institutet. The trial plans to enroll 900,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.